P-Adrenergic antagonists

Which of the following occurs in the treatment of glaucoma with a p-adrenergic antagonist ... 

Labetalol is a p-adrenergic antagonist which reduces blood pressure by blocking reflex sympathetic scimuiation of the heart. 

Propranolol [proe PRAN oh lole] is the prototype p-adrenergic antagonist and blocks both pi and p2 receptors. Sustained release preparations for once-a-day dosing are available. 

Tricyclic antidepressants Some p-adrenergic antagonists Some antiarrhythmic drugs... 

Biopharmaceuticals or pharmaceuticals dissolved in Tyrodes s solution to obtain at least 5 different concentrations Biopharmaceuticals and pharmaceuticals formulated by the CRO and require formulation analysis for concentration, homogeneity, and stability dl-soltalol, a P-adrenergic antagonist that prolongs cardiac action potential by selectively blocking the rapidly activating delayed rectifier potassium current (IKr)... 

The aqueous suppressants include the P-adrenergic antagonists, a-agonists, carbonic anhydrase inhibitors (CAIs topical and oral), and hyperosmotics (intravenous). The topical fiarms of this classification are used routinely in clinical practice. The oral and intravenous formulations are generally reserved fiar use under special circumstances. 

Side Effects and Clinical Problems Associated with Topical P-Adrenergic Antagonists... 

Ocular. Eye irritation, burning, tearing, and foreign body sensation can occur with the use of topical P-adrenergic antagonists however, these effects are usually short term. Notable long-term manifestations include dry eye and... 

Before use of topical P-adrenergic antagonists and following a careful history to assess the potential risk to the patient, it is advisable to evaluate the patient s blood pressure and pulse. Patients with concurrent use of oral P-adrenergic antagonists should typically avoid topical agents in the same class. Patients should be informed of the potential side effects of these medications and should discontinue their use if warranted. 

---